Completed PHASE1 INTERVENTIONAL 6-arm NCT01984775

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

An Evaluator-Blinded Study to Evaluate the Cumulative Irritation Potential of Topically-Applied GSK2894512 Cream in Healthy Subjects

Sponsor: Stiefel, a GSK Company

Conditions Psoriasis

Interventions GSK2894512 cream Negative control Positive control Vehicle cream

Updated 7 times since 2017 Last updated: Jun 14, 2017 Started: Oct 30, 2013 Primary completion: Jul 2, 2014 Completion: Jul 2, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01984775, this PHASE1 trial focuses on Psoriasis and remains completed. Sponsored by Stiefel, a GSK Company, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jul 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jul 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stiefel, a GSK Company

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States
• Hamburg, Germany